Home | Contact Us | Site Map
Dhtml Menu Css by Vista-Buttons.com v5.7
Slide background

NanoBio is developing

intranasal vaccines

based on our proprietary

nanoemulsion technology

Slide background

We are committed to

improving people's health

through bringing

safe and effective vaccines

to market

Slide background

Our technology deploys

nano-scale droplets

to deliver and adjuvant

vaccine antigens

Slide background

Our scientists are

studying how intranasal

vaccines can offer

greater protection

against respiratory &

sexually transmitted


  Recent News:  
NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice
NanoBio's Intranasal Vaccine for HSV-2 Demonstrates Efficacy in Both the Prophylactic & Therapeutic Guinea Pig Model
Merck Licenses NanoBio's Intranasal Vaccine Technology for RSV and Seasonal Influenza
NanoBio Awarded up to $10M in NIH Funding to Develop A Vaccine Adjuvant for Pandemic Influenza
  NanoBio and the U.K. Health Protection Agency Awarded Up to $24 Million in NIH Funding to Develop an Intranasal Anthrax Vaccine  


© NanoBio® Corporation 2014
NanoBio is a registered trademark of NanoBio Corporation.
All other company, brand, and product names are or may be trademarks of their respective holders. Website by Mellon & Associates, LLC.